PharmiWeb.com - Global Pharma News & Resources
07-Feb-2019

Radiopharmaceuticals - Market Analysis, Trends and Forecasts (2019-2024): Rise in Incidence of Neurological Disorders to Drive Growth - ResearchAndMarkets.com

The "Radiopharmaceuticals - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin America. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets in US$ Thousand by the following Segments:

  • Diagnostic Radiopharmaceuticals
  • Therapeutic Radiopharmaceuticals

The report profiles 61 companies including many key and niche players such as:

  • Actinium Pharmaceuticals Inc. (USA)
  • Alliance Medical (UK)
  • Alseres Pharmaceuticals Inc. (USA)
  • Avid Radiopharmaceuticals (USA)
  • Bayer HealthCare Pharmaceuticals (Germany)
  • Bracco Diagnostics Inc. (USA)
  • Cardinal Health Inc. (USA)
  • GE Healthcare (UK)
  • Ion Beam Applications S.A. (Belgium)
  • Immunomedics Inc. (USA)
  • Jubilant Pharma (India)
  • Lantheus Medical Imaging Inc. (USA)
  • Medi-Radiopharma Ltd. (Hungary)
  • Nordion Inc. (Canada)
  • Peregrine Pharmaceuticals Inc. (USA)
  • PETNET Solutions Inc. (USA)
  • Positron Corporation (USA)
  • Triad Isotopes Inc. (USA)

Topics Covered

1. INDUSTRY OVERVIEW

  • A Prelude
  • Current & Future Analysis
  • Diagnostic Radiopharmaceuticals: The Dominant Segment
  • Select Cardiology and Oncology Radiopharmaceuticals
  • New Therapeutic Radiopharmaceuticals to Drive Global Market
  • Market Drivers
  • Growing Acceptance in Cancer Treatment
  • Increasing Acceptance of Disease-Targeted Treatment
  • Growing Emphasis of Accurate Diagnosis
  • Expanding Molecular Imaging Applications
  • Market Restraints
  • Stringent Regulatory Guidelines for Manufacture, Storage and Usage
  • Global Supply Shortages
  • Price Sensitivity & Competition from Alternatives
  • Lack of Dosage Standards for Pediatric Patients Limits Radiopharmaceutical Efficacy
  • Unfounded Fears of Radiation Exposure Hinder Growth
  • Bottlenecks in Developing Markets
  • Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
  • Competition
  • Relevant Aspects of Radiopharmaceutical Production
  • Increasing Uptake of PET: A Prime Growth Driver
  • Non-Reactor Based TC-99m Production to Drive SPECT Growth
  • New Radiopharmaceuticals Drive Adoption of Molecular Imaging
  • PET and SPECT in Cardiovascular Imaging
  • Innovative Radiotracers
  • Key to PET & SPECT Success in Cardiovascular Imaging
  • Cardiac Amyloidosis Visualization
  • A Potential Application for PET
  • Application of PET in Drug Development to Expand Opportunities
  • Industry Focus Gears up for innovative Radiopharmaceuticals with Therapeutic Benefits
  • Innovative Radiopharmaceuticals to Boost Cardiac Applications
  • Intra-operative Lymphatic Mapping (ILM): Creates New Opportunities for Radiopharmaceuticals in Cancer Detection
  • Personalized Medicine to Drive Nuclear Medicine
  • Rise in Incidence of Neurological Disorders to Drive Growth
  • Battling Alzheimer's Disease
  • A Powerful Market Force for Nuclear Medicine
  • Combating the Shortage of RadioIsotopes

2. LONGSTANDING GROWTH DRIVERS

  • Rise in Incidence of Cancer
  • A Major Growth Driver
  • Cancer Prone Sites based on Age
  • Ageing Population
  • A Vital Demography
  • Global CVD Stats

3. PRODUCT OVERVIEW

  • Radiopharmaceuticals: A Definition
  • Mechanism of Action
  • Application of Radiopharmaceuticals
  • Radioactive Tracers for Diagnostic Imaging
  • Therapeutics
  • Research
  • Sterilization
  • Classification of Radiopharmaceuticals
  • Diagnostic Radiopharmaceuticals
  • Commonly Used Diagnostic Radiopharmaceutical Agents
  • Major Isotopes and their Diagnostic Applications
  • Advantages
  • Classification
  • Cardiology Diagnostics
  • Non-cardiology Diagnostics
  • Molecular Imaging Modalities in Radiopharmaceutical Diagnostics
  • Planar Imaging
  • Positron Emission Tomography (PET)
  • Applications of PET

4. PRODUCT INNOVATIONS/INTRODUCTIONS

  • ORA Launches NEPTIS xSeed Kitless Synthesizer
  • Advanced Accelerator Applications Resubmits NDA for Lutathera
  • Norgine B.V. Launches LYMPHOSEEK
  • IBA launches the Fixed IFP
  • Piramal Imaging and ISOLOGIC Innovative Radiopharmaceuticals Receive Approval
  • FDA Approves Netspot to Detect Rare Neuroendocrine Tumors
  • Blue Earth Diagnostics Bags FDA Approval for AxuminTM
  • EMA Issues Positive Opinion on Marketing Authorization Application for SomaKit TOC
  • IBA Unveils the Cyclone KIUBE Cyclotron
  • Advanced Accelerator Expands NETSPOTTM Supply Chain
  • Blue Earth Diagnostics and Siemens' PETNET Solutions Introduce AxuminTM (Fluciclovine F 18) Injection
  • Blue Earth Wins FDA Approval for PET Agent for Axumin
  • Zevacor to Develop SomaKit-TATE doses for AAA
  • Triad Isotopes Receives FDA Approval for Fludeoxyglucose F18 (18F FDG) and Sodium Fluoride F-18

5. RECENT INDUSTRY ACTIVITY

  • Telix Pharmaceuticals and ANMI Enter into Partnership for Commercialization of ANMI's 68Ga-HBED-CC-PSMA Kit
  • Telix Pharmaceuticals Signs Technology Licensing Agreement and Research Collaboration with the University of Melbourne
  • RadioMedix and ITM Enhter into Partnership Agreement for Distribution of Lutetium-177 in North America
  • Blue Earth Diagnostics Signs Exclusive Distribution Agreement with Seibersdorf Laboratories for the supply of Axumin
  • Blue Earth Diagnostics and GE Healthcare Sign Agreement to Manufacture Axumin
  • IRE-ELiT Signs Exclusive Long-Term Contract with Cardinal Health
  • Jubilant Acquires Radiopharmacy Business of Triad
  • ARTMS Products and GE Healthcare Partner to Expand Cyclotron-Produced Radioisotopes
  • Theragnostics Signs Partnership Agreement with ROTOP
  • Cyclotek and Telix Pharmaceuticals Sign Radiopharmaceutical Manufacturing Agreement
  • IBA and Philips Collaborate for Sales and Marketing of Proton Therapy in Brazil
  • Advanced Accelerator Applications Signs Agreement with Blue Earth Diagnostics to Supply Axumin
  • ARTMS Products Partners with Alliance Medical to Supply Tc-99m
  • Sofie Biosciences to Acquire Zevacor Pharma
  • IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Form Curium
  • GE Healthcare to Supply Radiopharmaceuticals to HealthTrust
  • IBA Signs Co-Marketing Agreement in North America with Nelco Worldwide
  • Telix Announces Product Development Partnership with Therapeia
  • IBA Signs ProteusONE Contracts with Proton Partners International
  • Cellectar Biosciences Selects Hamilton for Supply of CLR 131
  • Life Healthcare Acquires Alliance Medical Group
  • Lantheus Holdings Divests its Australian Radiopharmacy Servicing Business
  • ITEL Signed Agreement with AAA to Manufacture and Commercialize F-18 Radiopharmaceuticals
  • Zevacor Pharmato Manufacture and Supply Lomab-B for Pivotal Phase 3 SIERRA Trial
  • Blue Earth Diagnostics and Norsk Enter into Manufacturing and Distribution partnership for Fluciclovine (18F)

6. FOCUS ON SELECT PLAYERS

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 61 (including Divisions/Subsidiaries 69)

  • The United States (27)
  • Canada (4)
  • Japan (1)
  • Europe (28)
    • France (4)
    • Germany (5)
    • The United Kingdom (4)
    • Italy (2)
    • Rest of Europe (13)
  • Asia-Pacific (Excluding Japan) (8)
  • Africa (1)

For more information about this report visit https://www.researchandmarkets.com/research/64h5xr/radiopharmaceutica?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190207005412/en/

Editor Details

Last Updated: 07-Feb-2019